RLMD · Relmada Therapeutics, Inc. · Executive Compensation
$3.77
+0.04 (+1.07%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$408.55M
Shares
106.67M
Volume · Sep 30
999.53K
Avg daily vol (3M)
1.36M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Charles Ence | Chief Accounting and Compliance Officer | Appointed | 2025-12-15 |
| Maged Shenouda | Chief Financial Officer | Appointed | 2025-12-15 |
| Paul Kelly | Chief Operating Officer | Appointed | 2025-12-15 |
| Paul Kelly | Chief Operating Officer | Appointed | 2025-01-06 |
| Eric Schmidt | member of the Board of Directors | Resigned | 2023-09-06 |
| Sergio Traversa | Class II Director | Appointed | 2023-05-25 |
| Charles J. Casamento | Class II Director | Appointed | 2023-05-25 |
| Fabiana Fedeli | Class I director | Appointed | 2023-01-17 |